An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal
详细信息 查看全文
- 作者：Sofia Vitor ; Rui Tato Marinho ; José Gíria ; José Velosa
- 关键词：Portugal ; Liver disease ; Premature death ; Direct costs ; Mortality ; I110 ; I140 ; I180 ; H510
- 刊名：BMC Research Notes
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：9
- 期：1
- 全文大小：893 KB
- 参考文献：1.Ray KW, Brown RS, Terrault NA, Hashem ES. Burden of liver disease in the United States: summary of a Workshop. Hepatology. 2002;36:227–42.
2.Lee S, Woojin C, Kyung-Rae H. Socioeconomic costs of liver disease in Korea. Korean J Hepatol. 2011;17:274–91.PubMedCentral CrossRef PubMed
3.Iacobucci G. Liver disease rises in England while falling elsewhere in Europe, report says. BMJ. 2012;345:e7931.CrossRef PubMed
4.Eurostat European social statistics 2013 edition. (http://epp.eurostat.ec.europa.eu/cache/ITY_OFFPUB/KS-FP-13-001/EN/KS-FP-13-001-EN.PDF ).
5.Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European liver transplant registry (ELTR). J Hepatol. 2012;57:675–88.CrossRef PubMed
6.Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe. European association for the study of the liver (EASL). (http://www.easl.eu/assets/application/files/54ae845caec619f_file.pdf ).
7.Marinho RT, Giria J, Moura MC. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993–2005). World J. Gastroentero. 2007;13:1522–7.CrossRef
8.Cortez-Pinto H, Gouveia M, dos Santos Pinheiro L, et al. The burden of disease and the cost of illness attributable to alcohol drinking-results of a national study. Alcohol Clin Exp Res. 2010;34:1442–9.PubMed
9.Cortez-Pinto H, Marques-Vidal P, Monteiro E. Liver disease-related admissions in Portugal: clinical and demographic pattern. Eur J Hepatol. 2004;16:873–7.CrossRef
10.European Association for the Study of the Liver Press Office. Chronic hepatic diseases generate high costs to Europe. Separate Study links acute-on-chronic liver failure to high short-term mortality. (http://www.easl.eu/assets/application/files/f3263cb5942c12f_file.pdf ).
11.Nader LA, de Mattos AA, Bastos GA. Burden of liver disease in Brazil. Liver Int. 2014;. doi:10.1111/liv.12470 .PubMed
12.John RM, Sung HY, Max W. Economic cost of tobacco use in India, 2004. Tob Control. 2009;18:138–43.PubMedCentral CrossRef PubMed
13.Fenoglio P, Parel V, Kopp P. The social cost of alcohol, tobacco and illicit drugs in France, 1997. Eur Addict Res. 2003;9:18–28.CrossRef PubMed
14.Colagiuri S, Lee CM, Colagiuri R, et al. The cost of overweight and obesity in Australia. Med J Aust. 2010;192:260–4.PubMed
15.Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med. 2011;72:185–92.CrossRef PubMed
16.OECD Health Statistics 2014. Definitions, sources and methods. (http://www.oecd.org/health/healthdata(2014) ).
17.CDC. Premature mortality in the United States: public health issues in the use of the years of potential life lost. (http://www.cdc.gov/mmwr/preview/mmwrhtml/00001773.htm ).
18.Pordata. Taxa de actividade: total e por sexo (%). (http://www.pordata.pt/Portugal/Taxa+de+actividade+total+e+por+sexo+(percentagem)-547 ).
19.Pordata. Taxa de actividade: total e por grupo etário (%). (http://www.pordata.pt/Portugal/Taxa+de+actividade+total+e+por+grupo+etario+(percentagem)-1321 ).
20.Plano Nacional de Saúde 2012–2016. (http://pns.dgs.pt/nhp-in-english/ ).
21.George F. Causes of deaths in Portugal and challenges in prevention. Acta Med Port. 2012;25:61–3.PubMed
22.Rehm J, Dawson D, Frick U, et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res. 2012;38:1068–77.CrossRef
23.Anderson P, Chisholm D, Fuhr DC. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet. 2009;373(9682):2234–46.CrossRef PubMed
24.Chisholm D, Rehm J, Van Ommeren M, Monteiro M. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. J Stud Alcohol. 2004;65(6):782–93.CrossRef PubMed
25.Anderson P. The impact of alcohol advertising: ELSA project report on the evidence to strengthen regulation to protect young people. Utrecht: National foundation for alcohol prevention; 2007.
26.International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans (volume 59): Hepatitis viruses. Lyon: IARC; 1994.
27.Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989;2:1004–6.CrossRef PubMed
28.Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.CrossRef PubMed
29.Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.CrossRef PubMed
30.Sarrazin C, Berg T, Ross RS, et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol. 2010;48:289–351.CrossRef PubMed
31.van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.CrossRef PubMed
32.International Agency for Research on Cancer. Cancer. Mondial. (http://www-dep.iarc.fr ).
33.Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2012;3:353–67.CrossRef
34.Chhatwal J, Ferrante SA, Brass C, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health. 2013;16:973–86.CrossRef PubMed
35.Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ. 2014;17:65–76.CrossRef PubMed
36.Blázquez-Pérez A, SanMiguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics. 2013;31:919–31.CrossRef PubMed
37.Chen LP, Zhao J, Du Y, et al. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012;1:174–83.PubMedCentral CrossRef PubMed
38.Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2012;349:g3308.CrossRef
39.Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2012;28:81–7.CrossRef
40.McAfee JL. Developing an advanced practice nurse-led liver clinic. Gastroenterol Nurs. 2012;35:215–24.CrossRef PubMed - 作者单位：Sofia Vitor (1)
Rui Tato Marinho (1)
José Gíria (2)
José Velosa (1)
1. Department of Gastrenterology and Hepatology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Avenida Professor Egas Moniz, 1649-035, Lisbon, Portugal
2. Direcção Geral de Saúde, Alameda D. Afonso Henriques,45, 1049-005, Lisbon, Portugal - 刊物主题：Biomedicine general; Medicine/Public Health, general; Life Sciences, general;
- 出版者：BioMed Central
- ISSN：1756-0500
文摘
Background Liver disease, one of the most common causes of hospitalization worldwide, is particularly prevalent in Europe. This study aimed to determine the number of hospital discharges and admissions, mortality, premature death and costs associated with liver disease from the perspective of the National Health Service in Portugal.